Latest Government Investment News

Aland Equity Group expects its first capital-light property fund to deliver approximately $4.1 million in net returns by 30 June 2027. The forecast combines $3.37 million in management fees with a further $725,000 in investment returns, but remains subject to shareholder approval and successful lot sales.

Perpetual Resources and adviser GreenMet are assessing several US Government funding and financing pathways for the Nevada Scheelite tungsten project, as Washington prepares tighter defence sourcing rules. The interest is strategic, but no funding has been secured and the project remains without a Mineral Resource or Ore Reserve.

Island Pharmaceuticals has begun GMP production of Galidesivir, with the first 5kg batch targeted for an investigational Ebola treatment program in Uganda. A second batch is intended to support a pivotal Marburg animal study under the FDA’s Animal Rule pathway.

Perpetual Resources has added 62 lode claims around its Nevada Scheelite tungsten project, expanding the land position by 1,271.63 acres and more than 15 times the original patented claim area. The move broadens the project from a historic mine redevelopment opportunity into a larger exploration play, although the new ground remains untested.

Island Pharmaceuticals has obtained regulatory rights to reference critical Marburg-Angola virus natural history data, clearing a significant FDA hurdle for its antiviral Galidesivir. This milestone accelerates the path toward pivotal animal studies and potential FDA approval under the Animal Rule.

Acrow Limited secures final ACCC approval for its AusGroup Industrial Services acquisition, clearing the path for completion on 1 September 2026 and strengthening its foothold in Australia’s civil infrastructure sector.

Sierra Nevada Gold (ASX: SNX) has completed a $12.85 million capital raise to fund an aggressive Phase 2 drilling campaign at its As Safra Copper-Gold Project in Saudi Arabia, supported by strong institutional backing.

Island Pharmaceuticals has commissioned a second manufacturing run of its antiviral Galidesivir, aiming to stockpile up to 800 treatment courses by late 2026 to support rapid response to the fast-spreading Bundibugyo Ebola outbreak and biodefence efforts.

Lycopodium Limited reported a solid FY26 with $377.5 million revenue, a slight profit dip, and a 69% dividend hike, while setting sights on accelerated growth in the Americas.

Corporate Travel Management (ASX:CTD) has pushed back its FY25 and 1HFY26 financial statements to August 2026 due to intertwined UK customer remediation, financing negotiations, and audit complexities, while signalling significant goodwill impairments across multiple regions.

ReNerve Limited has appointed UG Medical to distribute its NervAlign nerve repair products in Malaysia, tapping into a fast-growing healthcare market backed by government investment.

FOS Capital, through its Aldridge Traffic Systems arm, has landed its largest contract to date, supplying advanced ITS lighting for a major Victorian freeway upgrade, lifting its order book to $9 million.